-
1.发明授权Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus 有权基于溶瘤非致病性仙台病毒的癌症免疫治疗方法和药物组合物公开(公告)号：US09526779B2
公开(公告)日：2016-12-27
申请号：US14438545
申请日：2013-11-21
申请人： Anna Senina
CPC分类号： A61K39/155 , A61K9/0019 , A61K39/0011 , A61K39/12 , A61K2039/515 , A61K2039/5152 , A61K2039/525 , A61K2039/54 , A61K2039/552 , A61K2039/585 , C12N7/00 , C12N2760/18834 , C12N2760/18871 , A61K2300/00
摘要： The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow deposited into ATCC as frozen allantoic fluid (deposit PTA-13024) and as lyophilized form (deposit PTA-121432) is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses.
摘要翻译： 本发明涉及免疫学和医学领域，更具体地涉及肿瘤学，并且可用于治疗患有癌和肉瘤的患者。 提供含有生物活性溶瘤仙台病毒株莫斯科PTA-13024的药物组合物，并且开发了治疗患有所述恶性肿瘤的患者的方法，包括将所述组合物施用于患者的身体。 仙台莫斯科菌株作为冷冻尿囊液（沉淀物PTA-13024）和冻干形式（沉积物PTA-121432）保藏在ATCC中，其特征在于高的溶瘤活性和人的安全性。 本发明的开发允许通过病毒作用直接消除恶性细胞并通过病毒诱导抗肿瘤免疫来提高治疗效果。
搜索结果
1 条记录 (耗时 0.01 秒)
